FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000362974> ?p ?o ?g. }

• W2000362974 endingPage "854" @default.
• W2000362974 startingPage "847" @default.
• W2000362974 abstract ": To assess the immunosuppressive capacity of hyperfractionated total lymphoid irradiation and cyclophosphamide for transplantation of unmodified allogeneic marrow in sensitized aplastic anemia patients. : From February 1983 to September 1990, 23 multiply transfused aplastic anemia patients underwent unmodified bone marrow transplantation from HLA genotypically identical sibling donors following preparation with 6 Gy hyperfractionated total lymphoid irradiation and 160 mg/kg cyclophosphamide. Graftversus-host disease prophylaxis included steroids in one patient, methotrexate in four, cyclosporine in seven, and methotrexate/cyclosporine in 12. There were 17 males and 6 females with a median age of 13 (range: 2.5–32). : One patient died early before engraftment of bacterial sepsis. Twenty-two patients were evaluable for engraftment. Three experienced graft failure including one primary, and two late graft failures associated with cyclosporine withdrawal. Acute graft-versus-host disease occurred in (≥ grade II in 6), and chronic graftversus-host disease in patients. Except for a patient who received total body irradiation for a second transplant, no patient in this series developed interstitial pneumonia. Fifteen patients are alive with follow-up of 38–125 months (median 68). The overall actuarial survival at 5 years is 69%, at 8 years it is 60%, with one late death. The survival of adult patients was similar to that of younger patients (≥ 16 years old: 63%, < 16 years old: 55%). The development of acute graft-versus-host disease adversely influenced survival (88% with Grade 0–I, 17% with grade II–IV; p = 0.002). No hypothyroidism or secondary malignancies have been documented in this series. : Pretransplant immunosuppression with 6 Gy of hyperfractionated total lymphoid irradiation and 160 mg/kg CY reduces but does not eliminate the incidence of graft failure in sensitized aplastic anemia patients. The dose and the mode of administration of total lymphoid irradiation in this trial may be associated with a lower incidence of late side effects. Survival is comparable to that obtained using preparative regimens without radiation." @default.
• W2000362974 created "2016-06-24" @default.
• W2000362974 creator A5010096299 @default.
• W2000362974 creator A5016295064 @default.
• W2000362974 creator A5027095419 @default.
• W2000362974 creator A5034640156 @default.
• W2000362974 creator A5036520753 @default.
• W2000362974 creator A5043966208 @default.
• W2000362974 creator A5058476408 @default.
• W2000362974 creator A5065109915 @default.
• W2000362974 creator A5065221178 @default.
• W2000362974 creator A5067712388 @default.
• W2000362974 creator A5075886051 @default.
• W2000362974 creator A5079103223 @default.
• W2000362974 creator A5080794141 @default.
• W2000362974 date "1994-07-01" @default.
• W2000362974 modified "2023-10-02" @default.
• W2000362974 title "Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia" @default.
• W2000362974 cites W1504310442 @default.
• W2000362974 cites W1510992271 @default.
• W2000362974 cites W1562876511 @default.
• W2000362974 cites W195094147 @default.
• W2000362974 cites W1968886587 @default.
• W2000362974 cites W1970770649 @default.
• W2000362974 cites W2014809795 @default.
• W2000362974 cites W2019455286 @default.
• W2000362974 cites W2031828870 @default.
• W2000362974 cites W2043502156 @default.
• W2000362974 cites W2052071946 @default.
• W2000362974 cites W2053278212 @default.
• W2000362974 cites W2055079427 @default.
• W2000362974 cites W206283783 @default.
• W2000362974 cites W2063307845 @default.
• W2000362974 cites W2072212675 @default.
• W2000362974 cites W2072397306 @default.
• W2000362974 cites W2105211798 @default.
• W2000362974 cites W2128015123 @default.
• W2000362974 cites W2154930008 @default.
• W2000362974 cites W2156895470 @default.
• W2000362974 cites W2319873259 @default.
• W2000362974 cites W2400052902 @default.
• W2000362974 cites W2416021341 @default.
• W2000362974 cites W248822908 @default.
• W2000362974 cites W254214252 @default.
• W2000362974 cites W3117239408 @default.
• W2000362974 cites W312886274 @default.
• W2000362974 cites W4237946219 @default.
• W2000362974 cites W4239791451 @default.
• W2000362974 cites W4252651670 @default.
• W2000362974 cites W4256128606 @default.
• W2000362974 doi "https://doi.org/10.1016/0360-3016(94)90575-4" @default.
• W2000362974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8040033" @default.
• W2000362974 hasPublicationYear "1994" @default.
• W2000362974 type Work @default.
• W2000362974 sameAs 2000362974 @default.
• W2000362974 citedByCount "13" @default.
• W2000362974 countsByYear W20003629742015 @default.
• W2000362974 crossrefType "journal-article" @default.
• W2000362974 hasAuthorship W2000362974A5010096299 @default.
• W2000362974 hasAuthorship W2000362974A5016295064 @default.
• W2000362974 hasAuthorship W2000362974A5027095419 @default.
• W2000362974 hasAuthorship W2000362974A5034640156 @default.
• W2000362974 hasAuthorship W2000362974A5036520753 @default.
• W2000362974 hasAuthorship W2000362974A5043966208 @default.
• W2000362974 hasAuthorship W2000362974A5058476408 @default.
• W2000362974 hasAuthorship W2000362974A5065109915 @default.
• W2000362974 hasAuthorship W2000362974A5065221178 @default.
• W2000362974 hasAuthorship W2000362974A5067712388 @default.
• W2000362974 hasAuthorship W2000362974A5075886051 @default.
• W2000362974 hasAuthorship W2000362974A5079103223 @default.
• W2000362974 hasAuthorship W2000362974A5080794141 @default.
• W2000362974 hasConcept C126322002 @default.
• W2000362974 hasConcept C141071460 @default.
• W2000362974 hasConcept C2776694085 @default.
• W2000362974 hasConcept C2776755627 @default.
• W2000362974 hasConcept C2778248108 @default.
• W2000362974 hasConcept C2778384902 @default.
• W2000362974 hasConcept C2778880498 @default.
• W2000362974 hasConcept C2780007613 @default.
• W2000362974 hasConcept C2781059491 @default.
• W2000362974 hasConcept C2781440808 @default.
• W2000362974 hasConcept C2911091166 @default.
• W2000362974 hasConcept C71924100 @default.
• W2000362974 hasConcept C90924648 @default.
• W2000362974 hasConceptScore W2000362974C126322002 @default.
• W2000362974 hasConceptScore W2000362974C141071460 @default.
• W2000362974 hasConceptScore W2000362974C2776694085 @default.
• W2000362974 hasConceptScore W2000362974C2776755627 @default.
• W2000362974 hasConceptScore W2000362974C2778248108 @default.
• W2000362974 hasConceptScore W2000362974C2778384902 @default.
• W2000362974 hasConceptScore W2000362974C2778880498 @default.
• W2000362974 hasConceptScore W2000362974C2780007613 @default.
• W2000362974 hasConceptScore W2000362974C2781059491 @default.
• W2000362974 hasConceptScore W2000362974C2781440808 @default.
• W2000362974 hasConceptScore W2000362974C2911091166 @default.
• W2000362974 hasConceptScore W2000362974C71924100 @default.
• W2000362974 hasConceptScore W2000362974C90924648 @default.
• W2000362974 hasIssue "4" @default.

• next